Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
2.050
+0.070 (3.54%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Innate Pharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Innate Pharma stock has a target of 11, which predicts an increase of 436.59% from the current stock price of 2.05.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Innate Pharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 → $11 | Strong Buy | Reiterates | $12 → $11 | +436.59% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +460.98% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +460.98% | Feb 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +460.98% | Jan 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +460.98% | Dec 9, 2024 |
Financial Forecast
Revenue This Year
62.34M
from 20.12M
Increased by 209.83%
Revenue Next Year
114.68M
from 62.34M
Increased by 83.96%
EPS This Year
0.09
from -0.61
EPS Next Year
0.45
from 0.09
Increased by 402.84%
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 193.2M | 302.4M | 125.5M | ||
| Avg | 62.3M | 114.7M | 72.4M | ||
| Low | 6.9M | 6.6M | 23.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 860.2% | 385.1% | 9.4% | ||
| Avg | 209.8% | 84.0% | -36.9% | ||
| Low | -65.9% | -89.4% | -79.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.41 | 1.88 | -0.63 |
| Avg | 0.09 | 0.45 | -0.61 |
| Low | -0.74 | -0.74 | -0.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 2,014.6% | - |
| Avg | - | 402.8% | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.